Original Work

643.

Lebedkina, M.⁺, Kovalkova, E., Andrenova, G., Dushkin, A., Chernov, A., Nikitina, E., Karaulov, A., Lysenko, M., Maurer, M., Kocatürk, E., and Fomina, D.: Chronic inducible urticaria – having more than one is common and clinically relevant. Front. Immunol. 2025: 16; 1584771. IF: TBD (IF 2024: 5.90)

642.

McLaren, J.⁺, Chon, Y., Gorski, K. S., Bernstein, J. A., Corren, J., Hayama, K., Jain, V., Lima, H., Sofen, H., Ponnarambil, S., Molfino, N. A., and Maurer, M.: Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study. J. Allergy Clin. Immunol. 2025: 155; 1945-1956. IF: TBD (IF 2024: 11.20)

641.

Soegiharto, R.⁺, van der Wind, E., Alizadeh Aghdam, M., Sørensen, J. A., van Lindonk, E., Bulut Demir, F., Mohammad Porras, N., Matsuo, Y., Kiefer, L., Knulst, A. C., Maurer, M, Ritchie, C., Rudenko, M., Kocatürk, E., Fachini Jardim Criado, R., Gregoriou, S., Bobylev, T., Kleinheinz, A., Takahagi, S., Hide, M., Giménez-Arnau, A. M., Salman, A., Oztas Kara, R., Sevimli Dikicier, B., van Doorn, M. B. A., Thomsen, S. F., van den Reek, J. M. P. A., and Röckmann, H.: Spectrum and impact of reported side effects of omalizumab in patients with chronic urticaria: a long-term multicentre real-world study. Clin. Exp. Allergy 2025: 55; 481-492. IF: TBD (IF 2024: 5.20)

640.

Magerl, M.⁺, Riedl, M. A., Arruda, L. K., Bauer, A., Berardi, A., Bernstein, J. A., Bouillet, L., Buckland, M., Buttgereit, T., Cohn, D. M., Craig, T., Criado, R. F., Du-Thanh, A., Fain, O., Gonçalo, M., Greve, J., Grumach, A. S., Guilarte, M., Katelaris, C., Kinaciyan, T., Latysheva, E. A., Lleonart, R., Llosa, O. C., Mansour, E., Grivcheva-Panovska, V., Parisi, C., Rosario Filho, N. A., Spinola Santos, A., Staubach, P., Valerieva, A., Valle, S. O. R., Danese, S., Ulloa, J., Audhya, P. K., and Maurer, M.: Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 Inhibitor. J. Allergy Clin. Immunol. Glob. 2025: 4; 100446. IF: N/A

639.

Siebenhaar, F., Brehler, R., Christen, D., Hartmann, K., Altrichter, S., Joest, M., aufm Kampe, K., Lang, C., Lippert, U., Mülleneisen, N., Ott, H., Panse, J., Pyatilova, P., Schmid-Grendelmeier, P., Staubach, P., Röseler, S., Ruëff, F., von Bubnoff, D., von Bubnoff, N., Wagner, N., Zuberbier, T., Maurer, M., Klimek, L., and Brockow, K.: Mastocytosis in the age of precision medicine – position paper of the German society of allergy (AeDA) on the management of indolent systemic mastocytosis. Allergo. J. Int. 2025; 34; 57-68. IF: N/A

638.

Goetzke, C. C.⁺, Massoud, M., Frischbutter, S., Guerra, G. M., Ferreira-Gomes, M., Heinrich, F., von Stuckrad, A. S. L., Wisniewski, S., Licha, J. R., Bondareva, M., Ehlers, L., Khaldi-Plassart, S., Javouhey, E., Pons, S., Trouillet-Assant, S., Ozsurekci, Y., Zhang, Y., Poli, M. C., Discepolo, V., Lo Vecchio, A., Sahin, B., Verboom, M., Hallensleben, M., Heuhsen, A. I., Astudillo, C., Espinosa, Y., Vial Cox, M. C., Dobbs, K., Delmonte, O. M., Montealegre Sanchez, G. A., Magliocco, M., Barron, K., Danielson, J., Petrov, L., Unterwalder, N., Sawitzki, B., Matz, M., Lehmann, K., Gratopp, A., von Bernuth, H., Burkhardt, L. M., Wiese, N., Peter, L., Schmueck-Henneresse, M., Amini, L., Maurer, M., Roehmel, J. F., Gewurz, B. E., Yonker, L. M., Witkowski, M., Kruglov, A., Mall, M. A., Su, H. C., Ozen, S., Radbruch, A., Belot, A., Durek, P., Kallinich, T., and Mashreghi, M. F.: TGFβ links EBV to multisystem inflammatory syndrome in children. Nature 2025: 640; 762-771. IF: TBD (IF 2024: 48.50)

637.

Kolkhir, P.⁺, Bieber, K., Hawro, T., Kridin, K., Ludwig, M. A., Olbrich, H., Metz, M., Vorobyef, A., Ludwig, R. J.^+*, and Maurer, M.^*: Mortality in adult patients with chronic spontaneous urticaria: a real world cohort study. J. Allergy Clin. Immunol. 2025: 155; 1290-1298. IF: TBD (IF 2024: 11.20)

636.

Neisinger, S.⁺, Kiefer, L., Salameh, P., Bonnekoh, H., Buttgereit, T., Gutsche, A., Herzog, L., Munoz, M., Pankow, A., Maurer, M., and Siebenhaar, F.: Addictive behavior is not a comorbidity of chronic spontaneous urticaria. Allergol. Int. 2025: 74; 325-326. IF: TBD (IF 2024: 6.70)

635.

Sousa-Pinto, B.⁺, Ramanauskaite, A.^*, Neisinger, S.^*, Witte-Händel, E., Giménez-Arnau, A. M., Guillet, C., Parisi, C. A. S., Katelaris, C. H., Fomina, D., Larenas-Linnemann, D., Garcia, E., Kocatürk, E., Siebenhaar, F., Lima, H., Kaidashev, I., Nasr, I., Ogueta Canales, I., Cherrez Ojeda, I., Hébert, J., Bousquet, J., Bernstein, J. A., Peter, J., Sanchez, J., Sousa, J. I. L., Kulthanan, K., Weller, K., Godse, K., Rutkowski, K., Lapina, L., Bouillet, L., Han, L. L., Ensina, L. F., Goncalo, M., Magerl, M., van Doorn, M., Metz, M., Khoshkhui, M., Hide, M., Türk, M., Kurjane, N., Stepanenko, R., Altrichter, S., Gil-Mata, S., Thomsen, S. F., Zuberbier, T., Tsaryk, V., Ye, Y.-M., Brzoza, Z., Zhao, Z., and Maurer, M.: Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: a CRUSE  mobile health study. Allergy 2025: 80; 750-761. IF: TBD (IF 2024: 12.00)

634.

Metz, M.^+*, Giménez-Arnau, A., Hide, M., Lebwohl, M., Mosnaim, G., Saini, S., Sussman, G., Szalewski, R., Haemmerle, S., Lheritier, K., Martzloff, E.-D., Seko, N., Wang, P., Zharkov, A., Maurer, M.^*, on behalf of the REMIX-1 and REMIX-2 investigators: Remibrutinib in chronic spontaneous urticaria. New Engl. J. Med. 2025: 392; 984-994. IF: TBD (IF 2024: 78.50)